Johnson & Johnson’s Biosense Webster today announced the first cases with its investigational Omnypulse catheter as part of the Omny-IRE clinical trial. The Omnypulse platform features the Omnypulse catheter and the Trupulse generator. Omny-IRE looks at the platform for mapping and treatment of symptomatic paroxysmal AFib during standard ablation procedures. Dr. Dr. Mattias Duytschaever performed […]
Biosense Webster
The biggest medtech personnel moves so far in 2023
More than halfway through 2023, we’ve seen plenty of movement in the personnel department across medtech. Last July, we broke down the biggest personnel moves in medtech so far in 2022. That was followed up by the full-year report in December. Through more than eight months, the changes atop medtech companies continue to arrive. Some […]
FDA approves multiple AFib ablation devices from Biosense Webster
Johnson & Johnson’s Biosense Webster announced today that the FDA approved several products in its cardiac ablation portfolio for zero fluoroscopy workflow. Products that received approval include the ThermoCool SmartTouch SF catheter, the most commonly used ablation catheter for radiofrequency ablation. The portfolio’s approved products also include the standard ThermoCool SmartTouch and Carto Vizigo bi-directional […]
J&J’s Biosense Webster launches AFib mapping catheter
Johnson & Johnson’s Biosense Webster announced today that it launched the Optrell mapping catheter with TrueRef technology. Irvine, California-based Biosense Webster designed Optrell as a high-density diagnostic catheter powered by its Carto 3 system. It features small electrodes arranged in a fixed array formation. These provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases. Optrell […]
J&J’s Biosense Webster gets a new president
Johnson & Johnson’s Biosense Webster this week announced it appointed Jasmina Brooks as president. As president, Brooks will be responsible for setting Biosense Webster’s global strategy and advancing its innovation agenda to position the company for continued growth. Brooks succeeds Michael Bodner, who is now the global head of heart recovery for J&J MedTech. She […]
Data supports Biosense Webster RF ablation for treating AFib
Johnson & Johnson MedTech’s Biosense Webster today announced data from a study of its QDOT Micro catheter for treating AFib. JACC: Clinical Electrophysiology published data from the Q-FFICIENCY study evaluating QDOT Micro’s safety and 12-month effectiveness. The study observed the use of the catheter in paroxysmal AFib ablation using a combination of high-power and conventional modes. […]
The biggest cardiology tech stories from ACC.23
Major medtech players presented a range of intriguing studies at a gathering of some of the biggest names in the cardiology tech space. Some of the hottest topics were covered this past week at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC) in New Orleans. Ablation, cardiac […]
Biosense Webster marks first cases with dual energy ablation tech
Biosense Webster today announced the first cases with its investigational Thermocool SmartTouch SF dual energy catheter for treating AFib. The system enables doctors performing an ablation to toggle between two types of energy: pulsed-field and radiofrequency. It appears to be the Johnson & Johnson MedTech subsidiary’s answer to the dual energy ablation tech coming out […]
How Johnson & Johnson is looking to lead the way in ablation
Celine Martin, Johnson & Johnson group chair, cardiovascular & specialty solutions (CSS) group, oversees high-growth areas at the company’s global MedTech business. Her leadership covers Acclarent, Biosense Webster, Cerenovus and Mentor. Together, those companies bring in more than $5 billion in annual sales with more than 14,000 employees. Over 25 years at Johnson & Johnson, […]
Biosense Webster launches HelioStar in Europe
Biosense Webster today launched its HelioStar balloon ablation catheter in Europe. Johnson & Johnson’s subsidiary Biosense Webster launched the radiofrequency balloon ablation catheter for catheter-based cardiac electrophysiological mapping of the atria when used with a multi-channel RF generator. According to the company, more than 11 million people in Europe have AFib. The expectation is that […]
J&J’s Biosense Webster launches mapping catheter for cardiac arrhythmias
Johnson & Johnson’s Biosense Webster announced today that it launched the Octaray mapping catheter with TRUEref technology. Irvine, California-based Biosense Webster designed Octaray for mapping cardiac arrhythmias, including AFib. It is powered by the company’s Carto 3 Version 7 system. The catheter has eight splines with improved electrode spacing options, according to a news release. […]